KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Net Margin (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Net Margin for 8 consecutive years, with 66.99% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 77824.0% to 66.99% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 638.87% through Dec 2025, up 11183.0% year-over-year, with the annual reading at 638.87% for FY2025, 6453.0% up from the prior year.
  • Net Margin hit 66.99% in Q4 2025 for Vir Biotechnology, up from 67975.42% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 106.57% in Q3 2021 to a low of 67975.42% in Q3 2025.
  • Historically, Net Margin has averaged 5825.25% across 5 years, with a median of 457.33% in 2023.
  • Biggest five-year swings in Net Margin: soared 859021bps in 2022 and later tumbled -5899571bps in 2025.
  • Year by year, Net Margin stood at 64.63% in 2021, then plummeted by -418bps to 205.63% in 2022, then crashed by -236bps to 690.85% in 2023, then dropped by -22bps to 845.23% in 2024, then soared by 92bps to 66.99% in 2025.
  • Business Quant data shows Net Margin for VIR at 66.99% in Q4 2025, 67975.42% in Q3 2025, and 9139.87% in Q2 2025.